Physician profile
Dae Rheem
NPI 1295915585
$10,490.98
in general payments reported to CMS, 2019-2025
41 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,875 · 2021: $2,421 · 2022: $1,977 · 2023: $1,109 · 2024: $1,109 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,881 · Education: $32.27 · Gift: $20.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.62 |
| Education | $32.27 |
| Gift | $20.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,267.73 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $1,329.25 | 2019-2025 | |
| Amgen INC. | $1,065.81 | 2019-2025 | Repatha, Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $694.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $688.77 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $587.80 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Glaxosmithkline, LLC. | $548.84 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $538.39 | 2019-2024 | Jardiance, Mounjaro |
| Ironwood Pharmaceuticals, INC | $386.90 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $293.70 | 2019-2023 | Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.66 | 2020-2023 | Jardiance |
| Nestle Healthcare Nutrition INC. | $261.09 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $174.71 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $157.69 | 2023-2025 | Ibsrela |
| Allergan, INC. | $147.67 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dae Rheem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.